Literature DB >> 9862675

Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses.

I Gramaglia1, A D Weinberg, M Lemon, M Croft.   

Abstract

Ox-40 and Ox-40 ligand (Ox-40L) are thought to be involved in T cell-APC interactions. However, their exact role in T cell responses is undefined. Using fibroblast transfectants expressing Ox-40L and/or B7-1, and CD4 cells from TCR transgenic mice, we investigated the effect of Ox-40 signaling on primary responses to the Ag pigeon cytochrome c. Ox-40 expression on naive CD4 cells peaked 2 to 3 days after activation, and was lost by 4 to 5 days. APCs with Ox-40L promoted partial activation of naive T cells with some IL-2 secretion, but were unable to enhance proliferation, unlike those with B7-1. APCs coexpressing Ox-40L with B7-1 induced large quantities of IL-2 and promoted proliferative responses that persisted for several days. Effector cells taken 5 days after naive T cell activation reexpressed Ox-40 within 4 h and responded strongly to APCs expressing Ox-40L, whereas B7-1 had little effect. Synergy was also seen between Ox-40L and B7-1, with primarily IL-2 being elevated, although IL-4 and IL-5 were also up-regulated. The most striking action was on effector T cell proliferation, which continued at high levels for up to 4 days, with little proliferation evident at this time in the absence of Ox-40 signals. These data suggest that Ox-40/Ox-40L interactions act after initial activation events to prolong clonal expansion and enhance effector cytokine secretion, and may be involved in promoting long-lived primary CD4 responses.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9862675

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  148 in total

1.  CD28-independent induction of experimental autoimmune encephalomyelitis.

Authors:  T Chitnis; N Najafian; K A Abdallah; V Dong; H Yagita; M H Sayegh; S J Khoury
Journal:  J Clin Invest       Date:  2001-03       Impact factor: 14.808

2.  Expansion of activated human naïve T-cells precedes effector function.

Authors:  J M Brenchley; D C Douek; D R Ambrozak; M Chatterji; M R Betts; L S Davis; R A Koup
Journal:  Clin Exp Immunol       Date:  2002-12       Impact factor: 4.330

3.  New insights on OX40 in the control of T cell immunity and immune tolerance in vivo.

Authors:  Xiang Xiao; Weihua Gong; Gulcin Demirci; Wentao Liu; Silvia Spoerl; Xiufeng Chu; D Keith Bishop; Laurence A Turka; Xian C Li
Journal:  J Immunol       Date:  2011-12-05       Impact factor: 5.422

Review 4.  T-cell activation and transplantation tolerance.

Authors:  Bhavana Priyadharshini; Dale L Greiner; Michael A Brehm
Journal:  Transplant Rev (Orlando)       Date:  2011-11-08       Impact factor: 3.943

Review 5.  T lymphocyte dependence of the antibody response to 'T lymphocyte independent type 2' antigens.

Authors:  A Jeurissen; J L Ceuppens; X Bossuyt
Journal:  Immunology       Date:  2004-01       Impact factor: 7.397

6.  Antigen inhibition of collagen-induced arthritis is associated with up-regulation of IL-4 mRNA and induction of Ox40 on T cells in draining lymph nodes.

Authors:  L Mattsson; K Lundberg; E Mussener; A Jansson; H Erlandsson Harris; P Larsson
Journal:  Clin Exp Immunol       Date:  2003-02       Impact factor: 4.330

7.  Essential role of OX40L on B cells in persistent alloantibody production following repeated alloimmunizations.

Authors:  Hiroshi Kato; Hidefumi Kojima; Naoto Ishii; Hidenori Hase; Yutaka Imai; Takashi Fujibayashi; Kazuo Sugamura; Testuji Kobata
Journal:  J Clin Immunol       Date:  2004-05       Impact factor: 8.317

8.  OX40 ligand fusion protein delivered simultaneously with the BCG vaccine provides superior protection against murine Mycobacterium tuberculosis infection.

Authors:  Robert J Snelgrove; Megan M Cornere; Lorna Edwards; Belinda Dagg; James Keeble; Angela Rodgers; Daphne E Lyonga; Graham R Stewart; Douglas B Young; Barry Walker; Tracy Hussell
Journal:  J Infect Dis       Date:  2012-02-07       Impact factor: 5.226

9.  Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity.

Authors:  William L Redmond; Stefanie N Linch; Melissa J Kasiewicz
Journal:  Cancer Immunol Res       Date:  2013-11-11       Impact factor: 11.151

10.  Cycling memory CD4+ T cells in HIV disease have a diverse T cell receptor repertoire and a phenotype consistent with bystander activation.

Authors:  Wei Jiang; Souheil-Antoine Younes; Nicholas T Funderburg; Joseph C Mudd; Enrique Espinosa; Miles P Davenport; Denise C Babineau; Scott F Sieg; Michael M Lederman
Journal:  J Virol       Date:  2014-02-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.